On Tuesday, Following U.S. Stocks were among the “Top Gainers“: bluebird bio (NASDAQ:BLUE), Array Biopharma (NASDAQ:ARRY), Celladon (NASDAQ:CLDN), Abercrombie & Fitch (NYSE:ANF)
bluebird bio Inc (NASDAQ:BLUE)’s shares picked up 2.25%, and closed at $117.12, hitting new 52-week high of $119.70. The stock has price to sale value of 150.18, however, price to book value is 7.01. With recent incline, the year-to-date (YTD) performance reflected a 26.21% gained below last year. During the past month the stock lose 33.11%, bringing three-month performance to 41.6% and six-month performance to 209.51%. The mean recommendation of analysts for this stock is 1.70. (where 1=Buy, 5=Sale).
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Its advanced product candidate is Lenti-D, which is in phase II/III clinical studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II clinical studies for the treatment of beta-thalassemia major and severe sickle cell disease (SCD) in France, in addition to a phase I study in the United States for the treatment of severe SCD.
Array Biopharma Inc (NASDAQ:ARRY), raised 1.62%, and closed at $8.16. The stock volatility for the week is 4.49%, while for the month remained 5.00%. The company holds consensus target price of $10.14.
If we consider EPS growth of the company, then we will notice the following observations:
The company showed -0.70 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -21.10% and Annual EPS growth for the past 5 years is considered as 23.70%.
The mean recommendation of analysts for this stock is 1.60. (where 1=Buy, 5=Sale).
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. Its proprietary clinical programs in Phase II clinical trial comprise ARRY-797, a p38 program for Lamin A/C-related dilated cardiomyopathy; and ARRY-502, a CRTh2 antagonist to treat Th2-driven allergic disease.
Celladon Corp (NASDAQ:CLDN), enhanced 1.57 %, and closed at $25.28, hitting new 52-week high of $26.16. The stock volatility for the week is 10.50%, while for the month it is 6.34%. The company has the market capitalization of $ 580.05M. The company holds the book value per share of 3.95, whereas cash per share is 4.09. Price to book value is estimated to be 6.40. Analysts mean recommendation for the stock is said to be 1.50 (where 1=Buy, 5=sale).
Celladon Corporation, a clinical-stage biotechnology company, focuses on developing treatments for heart failure, diabetes, and neurodegenerative diseases. The companys lead product candidate comprises MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that results in inadequate pumping of the heart.
Abercrombie & Fitch Co (NYSE:ANF), rose 1.40%, and closed at $21.01. The company has the market capitalization of $1.44B. In the last trading session 4.6M shares changed hands as compared to its average volume of 3.66M shares. The beta value of the stock is 1.97. On the other hand the stock’s volatility for the week is 5.86%, and for the month is 3.83%. The stock price to book value is $1.07, however price to sale value is $0.37. Analyst’s mean recommendation regarding this stock is 3.00. (where 1=Buy, 5=Sale).
Abercrombie & Fitch Co., through its subsidiaries, operates as a specialty retailer of casual apparel for men, women, and kids. It operates through three segments: U.S. Stores, International Stores, and Direct-to-Consumer. The company sells various products, counting casual sportswear apparel comprising knit and woven shirts, graphic T-shirts, fleece, jeans and woven pants, shorts, sweaters, and outerwear; personal care products; and accessories for men, women, and kids under the Abercrombie & Fitch, abercrombie kids, and Hollister brand names.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
